Answers are grounded in this paper and cite their sources.
Background This study was designed to investigate the underlying mechanisms of Tanshinone ⅡA using an in vitro model of lipopolysaccharide (LPS)-induced human periodontal ligament fibroblasts (HPDLFs). Methods An LPS-induced periodontitis model was constructed with HPDLFs. Cell counting kit-8 (CCK-8) and flow cytometry assays were used to assess cell viability and apoptosis of model HPDLFs. The content of inflammation-relevant cytokines was quantified by ELISA, and the autophagosome formation was observed under a transmission electron microscopy. Further, correlations with mediators related to autophagy and protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway were tested via quantitative PCR and immunoblotting assays. For validation, rescue assays were performed using autophagy inhibitor 3-MA or AKT activator SC79. Results Tanshinone ⅡA effectively restored cell viability, inhibited apoptosis, and significantly downregulated the expression of inflammatory cytokines TNF-α, IL-6, IL-8, and IL-1β. Tanshinone IIA promoted autophagosome formation, upregulated the expression of Beclin 1, downregulated p62 levels, and simultaneously inhibited the phosphorylation of the AKT/mTOR signaling pathway. Intervention experiments using the autophagy inhibitor 3-MA and the AKT activator SC79 confirmed that the protective effects of Tanshinone IIA was dependent on the activation of autophagy and inhibition of the AKT/mTOR pathway. This study is limited to in vitro assays in LPS-induced HPDLFs, and lacks in vivo validation. Conclusion This study further evaluated the anti-inflammatory property of Tanshinone ⅡA on LPS-induced HPDLFs, and proposed that the activation of autophagy and suppression of AKT/mTOR pathway may account for such effects.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: